Mirum reports volixibat meets primary endpoint in cholangitis study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Mirum reports volixibat meets primary endpoint in cholangitis study
(NASDAQ: MIRM) Delayed: 108.35 +0.58 (0.54%)
Previous Close $107.77    52 Week High $ 
Open $105.48    52 Week Low $ 
Day High $110.18    P/E N/A 
Day Low $105.18    EPS $ 
Volume 546,589